Compare CBIO & EFSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CBIO | EFSI |
|---|---|---|
| Founded | 2003 | 1881 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Major Banks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.6M | 214.3M |
| IPO Year | N/A | N/A |
| Metric | CBIO | EFSI |
|---|---|---|
| Price | $13.13 | $39.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $25.60 | ★ $39.50 |
| AVG Volume (30 Days) | ★ 207.9K | 13.6K |
| Earning Date | 11-06-2025 | 10-23-2025 |
| Dividend Yield | N/A | ★ 3.13% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | N/A | ★ $66,122,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $27.28 |
| P/E Ratio | ★ N/A | $18.59 |
| Revenue Growth | N/A | ★ 3.18 |
| 52 Week Low | $9.81 | $28.70 |
| 52 Week High | $21.40 | $40.38 |
| Indicator | CBIO | EFSI |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 71.86 |
| Support Level | $13.35 | $39.51 |
| Resistance Level | $15.58 | $40.38 |
| Average True Range (ATR) | 1.32 | 0.82 |
| MACD | -0.04 | 0.29 |
| Stochastic Oscillator | 17.28 | 77.29 |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.